CL2021001034A1 - Métodos y composiciones para terapia con células oculares - Google Patents

Métodos y composiciones para terapia con células oculares

Info

Publication number
CL2021001034A1
CL2021001034A1 CL2021001034A CL2021001034A CL2021001034A1 CL 2021001034 A1 CL2021001034 A1 CL 2021001034A1 CL 2021001034 A CL2021001034 A CL 2021001034A CL 2021001034 A CL2021001034 A CL 2021001034A CL 2021001034 A1 CL2021001034 A1 CL 2021001034A1
Authority
CL
Chile
Prior art keywords
cells
methods
ocular
cell therapy
compositions
Prior art date
Application number
CL2021001034A
Other languages
English (en)
Inventor
Frada Berenshteyn
Bo Han
Xueshi Hao
Jessica Heyder
Timothy Z Hoffman
Qihui Jin
Arnaud Lacoste
Jun Liu
Yahu Liu
Tingting Mo
Bradley Andrew Murray
Daniel Joseph O'connell
Jianfeng Pan
Yun Feng Xie
Shanshan Yan
Yefen Zou
Original Assignee
Novartis Ag
Intellia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Intellia Therapeutics Inc filed Critical Novartis Ag
Publication of CL2021001034A1 publication Critical patent/CL2021001034A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/08—Coculture with; Conditioned medium produced by cells of the nervous system
    • C12N2502/085—Coculture with; Conditioned medium produced by cells of the nervous system eye cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención provee células oculares, genéticamente modificadas por un sistema CRISPR dirigido a la expresión de B2M para terapia celular ocular. La invención provee además métodos para generar una población expandida de células oculares genéticamente modificadas, por ejemplo, células madre limbares (LSC) o células endoteliales corneales (CEC), en donde las células se expanden con el uso de un inhibidor de LATS y la expresión de B2M en las células se ha reducido o eliminado. La presente invención además provee poblaciones celulares, preparaciones, usos y métodos de terapia que comprenden dichas células.
CL2021001034A 2018-10-26 2021-04-22 Métodos y composiciones para terapia con células oculares CL2021001034A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862750962P 2018-10-26 2018-10-26
US201962902639P 2019-09-19 2019-09-19

Publications (1)

Publication Number Publication Date
CL2021001034A1 true CL2021001034A1 (es) 2021-11-19

Family

ID=68393038

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021001034A CL2021001034A1 (es) 2018-10-26 2021-04-22 Métodos y composiciones para terapia con células oculares

Country Status (22)

Country Link
US (1) US20200131474A1 (es)
EP (1) EP3870289A1 (es)
JP (1) JP2022505658A (es)
KR (1) KR20210069075A (es)
CN (1) CN112969472A (es)
AU (1) AU2019365590A1 (es)
BR (1) BR112021007628A2 (es)
CA (1) CA3116512A1 (es)
CL (1) CL2021001034A1 (es)
CO (1) CO2021005289A2 (es)
CR (1) CR20210196A (es)
CU (1) CU20210033A7 (es)
EC (1) ECSP21028556A (es)
IL (1) IL282447A (es)
JO (1) JOP20210080A1 (es)
MX (1) MX2021004532A (es)
PE (1) PE20211114A1 (es)
PH (1) PH12021550761A1 (es)
SG (1) SG11202102615RA (es)
TW (1) TW202030324A (es)
UY (1) UY38427A (es)
WO (1) WO2020084580A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202109655VA (en) 2015-12-04 2021-10-28 Novartis Ag Compositions and methods for immunooncology
MX2019011272A (es) 2017-03-22 2019-10-24 Novartis Ag Composiciones y metodos para inmunooncologia.
JOP20190257A1 (ar) * 2017-04-28 2019-10-28 Novartis Ag مركبات أريل غير متجانسة ثنائية الحلقة مندمجة 6-6 واستخدامها كمثبطات lats
WO2021113515A1 (en) * 2019-12-03 2021-06-10 The Schepens Eye Research Institute, Inc. Injectable hydrogels for cell delivery to the vitreous
EP4142879A1 (en) * 2020-04-27 2023-03-08 Novartis AG Methods and compositions for ocular cell therapy
EP4326290A2 (en) * 2021-04-20 2024-02-28 Walking Fish Therapeutics, Inc. Engineering b cell-based protein factories to treat serious diseases
EP4392561A1 (en) * 2021-08-27 2024-07-03 Metagenomi, Inc. Enzymes with ruvc domains
CN116286905B (zh) * 2023-05-11 2023-08-15 内蒙古大学 牛源化CRISPR/boCas9基因编辑系统、方法及应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2770497B2 (ja) 1988-11-24 1998-07-02 吉富製薬株式会社 トランス―４―アミノ（アルキル）―１―ピリジルカルバモイルシクロヘキサン化合物およびその医薬用途
CA2117096C (en) 1991-09-06 1997-11-04 Masafumi Arita 4-amino(alkyl)cyclohexane-1-carboxamide compound and use thereof
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
US5989835A (en) 1997-02-27 1999-11-23 Cellomics, Inc. System for cell-based screening
DE69737631T3 (de) 1996-08-12 2011-08-18 Mitsubishi Tanabe Pharma Corp. MEDIKAMENTE ENTHALTEND Rho-KINASE INHIBITOREN
JPH11130751A (ja) 1997-10-30 1999-05-18 Yoshitomi Pharmaceut Ind Ltd アミド化合物およびそれらの酸付加塩の標識化合物
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
JP4851003B2 (ja) 2000-12-21 2012-01-11 田辺三菱製薬株式会社 肝臓障害に基づく疾患の予防・治療剤
US20030125344A1 (en) 2001-03-23 2003-07-03 Bayer Corporation Rho-kinase inhibitors
EP1383771A1 (en) 2001-04-20 2004-01-28 Vertex Pharmaceuticals Incorporated 9-deazaguanine derivatives as inhibitors of gsk-3
US7199147B2 (en) 2001-06-12 2007-04-03 Dainippon Sumitomo Pharma Co., Ltd. Rho kinase inhibitors
US6642263B2 (en) 2001-11-19 2003-11-04 Iconix Pharmaceuticals Inc. Modulators of Rho C activity
AU2003202263A1 (en) 2002-01-10 2003-07-30 Bayer Healthcare Ag Roh-kinase inhibitors
CA2473910C (en) 2002-01-23 2011-03-15 Bayer Pharmaceuticals Corporation Pyrimidine derivatives as rho-kinase inhibitors
JP4469179B2 (ja) 2002-01-23 2010-05-26 バイエル ファーマセチカル コーポレーション Ｒｈｏキナーゼ阻害剤としてのピリミジン誘導体
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
GB0206860D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
US7645878B2 (en) 2002-03-22 2010-01-12 Bayer Healthcare Llc Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
US20050182040A1 (en) 2002-04-03 2005-08-18 Naonori Imazaki Benzamide derivatives
CA2503646C (en) 2002-10-28 2011-09-27 Bayer Healthcare Ag Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors
JP4869068B2 (ja) 2003-06-19 2012-02-01 スミスクライン ビーチャム コーポレーション 化合物
WO2005003101A2 (en) 2003-07-02 2005-01-13 Biofocus Discovery Limited Pyrazine and pyridine derivatives as rho kinase inhibitors
CN1242058C (zh) * 2004-04-09 2006-02-15 西北农林科技大学 表皮干细胞构建组织工程化角膜上皮植片的制备方法及其用途
DK2800811T3 (en) 2012-05-25 2017-07-17 Univ Vienna METHODS AND COMPOSITIONS FOR RNA DIRECTIVE TARGET DNA MODIFICATION AND FOR RNA DIRECTIVE MODULATION OF TRANSCRIPTION
CA2913869C (en) 2013-05-29 2023-01-24 Cellectis New compact scaffold of cas9 in the type ii crispr system
WO2015048577A2 (en) 2013-09-27 2015-04-02 Editas Medicine, Inc. Crispr-related methods and compositions
JP2017522016A (ja) * 2014-06-27 2017-08-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 培養哺乳動物輪部幹細胞、その産生方法及びその使用
EP3169776A4 (en) 2014-07-14 2018-07-04 The Regents of The University of California Crispr/cas transcriptional modulation
WO2016073955A2 (en) 2014-11-06 2016-05-12 President And Fellows Of Harvard College Cells lacking b2m surface expression and methods for allogeneic administration of such cells
AU2016261600B2 (en) * 2015-05-08 2021-09-23 President And Fellows Of Harvard College Universal donor stem cells and related methods
SG10202109655VA (en) 2015-12-04 2021-10-28 Novartis Ag Compositions and methods for immunooncology
JP2018537112A (ja) 2015-12-18 2018-12-20 サンガモ セラピューティクス， インコーポレイテッド Ｍｈｃ細胞受容体の標的化破壊
US11564942B2 (en) 2016-02-19 2023-01-31 The General Hospital Corporation Methods for generating universal and custom MHC/HLA-compatible hematopoietic progenitor cells
WO2017212072A1 (en) 2016-06-10 2017-12-14 Umc Utrecht Holding B.V. Human leukocyte antigen restricted gamma delta t cell receptors and methods of use thereof
EP3519562A4 (en) 2016-09-29 2020-03-25 Nantkwest, Inc. NK-92 HLA CLASS I DEFICIENT CELLS WITH REDUCED IMMUNOGENICITY
JP2020505025A (ja) * 2017-01-13 2020-02-20 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 免疫工学的な改変をした多能性細胞
JOP20190257A1 (ar) * 2017-04-28 2019-10-28 Novartis Ag مركبات أريل غير متجانسة ثنائية الحلقة مندمجة 6-6 واستخدامها كمثبطات lats
CN115671398B (zh) * 2022-11-22 2024-03-01 首都医科大学附属北京同仁医院 一种3d打印仿生角膜缘移植物及其制备方法和用途

Also Published As

Publication number Publication date
KR20210069075A (ko) 2021-06-10
CO2021005289A2 (es) 2021-05-10
CR20210196A (es) 2021-07-27
ECSP21028556A (es) 2021-05-31
BR112021007628A2 (pt) 2021-10-13
PH12021550761A1 (en) 2021-12-13
JOP20210080A1 (ar) 2023-01-30
SG11202102615RA (en) 2021-05-28
US20200131474A1 (en) 2020-04-30
IL282447A (en) 2021-06-30
CN112969472A (zh) 2021-06-15
TW202030324A (zh) 2020-08-16
JP2022505658A (ja) 2022-01-14
AU2019365590A1 (en) 2021-04-22
MX2021004532A (es) 2021-07-16
UY38427A (es) 2020-05-29
EP3870289A1 (en) 2021-09-01
CU20210033A7 (es) 2021-12-08
WO2020084580A1 (en) 2020-04-30
CA3116512A1 (en) 2020-04-30
PE20211114A1 (es) 2021-06-22

Similar Documents

Publication Publication Date Title
CL2021001034A1 (es) Métodos y composiciones para terapia con células oculares
DOP2020000071A (es) Proteínas trispecificas y métodos de uso
PH12021550805A1 (en) Methods and Compositions for Editing RNAs
AU2018262698A1 (en) Expansion of gamma delta T cells, compositions, and methods of use thereof
MX2020005503A (es) Metodos para activar, modificar y expandir linfocitos t gamma delta para el tratamiento del cancer y de neoplasias malignas relacionadas.
WO2019014395A8 (en) GENERATION OF WATER-SOLUBLE CANNABINOID COMPOUNDS IN PLANT CELL SUSPENSION YEAST AND CROPS AND MATERIAL COMPOSITIONS
MX2021012645A (es) Metodos y composiciones para editar acidos ribonucleicos (arn).
UY37564A (es) Aislados de lysinibacillus y usos de los mismos
MX2022000497A (es) Edicion de acido ribonucleico (arn) dirigido aprovechando la adenosina desaminasa que actua sobre acido ribonucleico endogeno (adar) utilizando acidos ribonucleicos (arn) modificados geneticamente.
CO2020010303A2 (es) Conjugados de il-15, y sus usos
BRPI0506474A (pt) sistema de tecido com células tronco não diferenciadas derivadas no limbus da córnea
CU24495B1 (es) Compuestos que expanden las células hematopoyéticas y método ex vivo para expandir las células hematopoyéticas
BR112019000693A2 (pt) composições de muc1- car e métodos para uso
AR068507A1 (es) Construcciones vector fluorocarbonado-antigeno para el suministro de antigenos ifluenza
CL2021000855A1 (es) Replicones basados en alfavirus para la administración de bioterapias.
ECSP20084373A (es) Tiofencarboxamidas sustituidas y análogos de las mismas
BR112017006533A2 (pt) usos de trealose em suspensões celulares
ECSP20024456A (es) Uso de composiciones que contienen Streptomyces melanosporofaciens AGL225 en el control de enfermedades de las plantas
BR112022011169A2 (pt) Métodos para geração de células-tronco hematopoiéticas
MX2020004063A (es) Sistemas y metodos para producir celulas b modificadas geneticamente para expresar anticuerpos seleccionados.
MA50279A (fr) Enrichissement de cellules coexprimant nkx6.1 et le peptide c, dérivées in vitro à partir de cellules souches
BR112023024434A2 (pt) Células hipoimunogênicas que compreendem hla-e ou hla-g geneticamente modificadas
CL2023003108A1 (es) Ingeniería de fábricas de proteínas basadas en células b para tratar enfermedades graves
CL2018001138A1 (es) Un método ex vivo para probar la respuesta celular de las poblaciones de células primarias a una droga o combinación de drogas
CO2023009612A2 (es) Composiciones y métodos para reducir los hla-a en una célula